EBS Emergent BioSolutions Inc.

Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 20, 2021 at 9:00am EDT

Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 20, 2021 at 9:00am EDT

GAITHERSBURG, Md., May 06, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that its 2021 Annual Meeting of Stockholders will be held in a virtual-only format via live audio webcast on Thursday, May 20, 2021 at 9:00 AM EDT.  

HOW TO PARTICIPATE IN THE VIRTUAL ANNUAL MEETING

As described in the proxy materials, stockholders of record as of the record date of March 25, 2021 are eligible to participate in and ask questions during the Virtual Annual Meeting by visiting and entering their 16-digit Control Number provided on the proxy card, voting instruction form or notice received from the Company to log into this website. Only one stockholder per 16-digit Control Number can access the Virtual Annual Meeting.

Beneficial owners of shares held in street name will need to follow the instructions provided by the broker, bank or other nominee that holds their shares.  

Those without a Control Number may attend as guests in listen-only mode and will not have the option to vote their shares or ask questions during the Virtual Annual Meeting.

ALL PARTICIPANTS ARE ENCOURAGED TO LOG IN AND ACCESS THE WEBCAST 15 MINUTES BEFORE THE VIRTUAL ANNUAL MEETING BEGINS.

Further instructions on how to attend, participate in and vote at the Virtual Annual Meeting, including how to demonstrate your ownership of the Company’s common stock as of the record date, are available at .

A replay of the audio webcast will be made available on the .

About Emergent BioSolutions

Emergent BioSolutions is a global life sciences company whose mission is to protect and enhance life. Through our specialty products and contract development and manufacturing services, we are dedicated to providing solutions that address public health threats. Through social responsibility, we aim to build healthier and safer communities. We aspire to deliver peace of mind to our patients and customers so they can focus on what’s most important in their lives. In working together, we envision protecting or enhancing 1 billion lives by 2030. For more information, visit our and follow us on , , and .

Investor Contact:

Robert G. Burrows

Vice President, Investor Relations

240-631-3280

   

Media Contact:

Matt Hartwig

Director, Media Relations

 



EN
06/05/2021

Underlying

EBSEmergent BioSolutions Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Emergent BioSolutions Inc.

 PRESS RELEASE
Free
EBS Emergent BioSol...

Emergent BioSolutions Reports Second Quarter 2025 Financial Results

Emergent BioSolutions Reports Second Quarter 2025 Financial Results Second Quarter 2025 Total Revenues of $140.9 million, above Q2 guidance by $21 millionSecond Quarter 2025 Net Loss of $12.0 million and Net Loss Margin of (9)%, an improvement of 96% and 10,200 bps, respectively, versus prior yearSecond Quarter 2025 Gross Margin % of 36% and Adjusted Gross Margin % of 49%, an expansion of 6,200 bps and 2,300 bps, respectively, versus prior yearSecond Quarter 2025 Adjusted EBITDA of $28.5 million, an increase of 382% versus prior yearSecond Quarter 2025 Adjusted EBITDA Margin of 20% of Total...

August 6, 2025 1 EN
 PRESS RELEASE
Free
EBS Emergent BioSol...

New Publication in Expert Review of Anti-infective Therapy Evaluates B...

New Publication in Expert Review of Anti-infective Therapy Evaluates Brincidofovir as Potential Antiviral Treatment for Mpox Ongoing mpox outbreak continues to be a global health threat and is driving need for greater therapeutic research and innovation GAITHERSBURG, Md., July 28, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced the publication of a comprehensive review article, "Brincidofovir in the Era of Mpox," in the peer-reviewed journal Expert Review of Anti-infective Therapy.1 This publication includes an overview of brincidofovir, in vitro and in v...

July 28, 2025 1 EN
 PRESS RELEASE
Free
EBS Emergent BioSol...

Emergent Applauds Availability of Over-the-Counter Naloxone in U.S. Ho...

Emergent Applauds Availability of Over-the-Counter Naloxone in U.S. House of Representatives GAITHERSBURG, Md., July 28, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announces its recognition of the U.S. House of Representatives for adding over-the-counter (OTC) naloxone to every AED location in its buildings, providing direct access to first responders and anyone coming across an individual who may be experiencing an opioid overdose. This effort has been led by Representative Buddy Carter (R-GA), with his team and congressional constituents, who have kept this pu...

July 28, 2025 1 EN
 PRESS RELEASE
Free
EBS Emergent BioSol...

Emergent BioSolutions to Report Second Quarter 2025 Financial Results ...

Emergent BioSolutions to Report Second Quarter 2025 Financial Results on August 6, 2025 GAITHERSBURG, Md., July 15, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Wednesday, August 6, 2025, at 5:00 pm eastern time to discuss the financial results for the second quarter of 2025. Participants can access the conference call live via and also by visiting the page of Emergent’s website. To participate via telephone, please register in advance at this . Upon registration, all telephone participants will receive a confirmation email detailing ho...

July 15, 2025 1 EN
 PRESS RELEASE
Free
EBS Emergent BioSol...

Emergent BioSolutions Secures $51.9 Million Contract Modification Awar...

Emergent BioSolutions Secures $51.9 Million Contract Modification Award for CNJ-016® [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV) as part of U.S. Biodefense Preparedness Efforts GAITHERSBURG, Md., July 08, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced a contract modification has been secured to deliver CNJ-016® [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV) to the Administration for Strategic Preparedness and Response (ASPR), part of the U. S. Department of Health and Human Services (HHS), for smallpox preparedness. ASPR exercised an opt...

July 8, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch